Rituximab-based regimens are the standard-of-care first-line therapy for localized-stage FL patients.
By Niharika Dandamudi, Senior Epidemiologist
21 April 2016
I am a Senior Epidemiologist at Datamonitor Healthcare. I have a Master’s in Public Health from Birla Institute of Tec...
Read full bio
Rituximab-based regimens are the standard first-line therapies for FL patients with localized-stage disease. Datamonitor Healthcare’s primary research survey indicated that R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) is utilized as a first-line induction therapy across the US, Japan, and five major EU markets, with 29% of patients receiving the regimen. While R-CHOP is the dominant therapy in the US, Japan, France, and Spain, most patients in Germany receive bendamustine plus rituximab (43%). In Italy and the UK, patients most commonly receive rituximab monotherapy (27%) and R-CVP (rituximab, cyclophosphamide, vincristine, and prednisone) (33%), respectively.
Generally, rituximab in combination with other drug regimens significantly improves progression-free survival and overall survival in FL patients. The two most commonly used regimens for the treatment of FL include R-CHOP and R-CVP (Fowler, 2011). Bendamustine and rituximab is also considered as a very good treatment option for FL patients with localized disease instead of R-CHOP or R-CVP because of lesser side-effects and increased progression-free survival (Ghielmini, 2010).
Proportions of localized-stage (I/II) follicular lymphoma patients receiving first-line induction therapies, by country (%), 2016
Source: Datamonitor Healthcare’s proprietary follicular lymphoma survey, January 2016
Datamonitor Healthcare’s FL: Treatment provided a detailed analysis of FL diagnosis, patient segmentation, current and future prescribing patterns, factors influencing decision-making and key treatment challenges.
Get your free demo today – simply fill out the form to the right.